To model the functional impact of KEAP1 expression on melanoma tumor growth and response to immune checkpoint inhibition in vivo, we used the well-established B16-OVA model, in which anti-PD1 antibody treatment mediates a potent anti-tumor response17. Here, KEAP1 is linked to neoplasm.